Kevin has almost 20 years of experience in developing new genomic technologies, and has over 40 published articles in peer reviewed journals, and more than 30 published patents and patent applications.   His technical expertise spans the fields of molecular biology, surface chemistry, assay technology development, electrophysiology, and nanofabrication.  He has used these skills to oversee the development of assay technologies and their integration with micro/nanofabricated devices.Currently, Kevin is Cofounder, VP and CTO of Encodia, which is enabling “Next-Gen” proteomics by creating scalable and parallelized solutions to protein analysis.  Kevin is formerly Senior Director of Advanced Research at Illumina, where he spent his last 16 years overseeing R&D scientists and projects aimed at developing both DNA array and Next-Generation Sequencing (NGS) assays and technologies.  These efforts helped Illumina grow from a fledgling start-up to the world’s leading provider of Genomics and NGS instruments and assays. 

Prior to Illumina, Kevin was a research scientist at Affymetrix, developing array-based resequencing and genotyping technology.   This effort was preceded by a postdoctoral research at Stanford University studying the electrophysiology of cystic fibrosis.  Kevin holds a PhD in biophysics and MS in physics from Stanford University, and a B.A. in math/physics from St. Olaf College.